Compare Novavax Inc (NVAX) vs Old National Bancorp Common Stock (ONB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Old National Bancorp Common Stock — how do they compare? Novavax Inc trades at $12.49 (market cap $2.11B), while Old National Bancorp Common Stock trades at $24.48 (market cap $9.42B). The key difference: Old National Bancorp Common Stock is far larger — about 4.5× Novavax Inc's market cap, and Old National Bancorp Common Stock pays a 2.36% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Old National Bancorp Common Stock for 0 Days on average.
| NVAX | ONB | |
|---|---|---|
Market Cap | $2.11B | $9.42B |
Volume | 8,376,831 | 4,606,260 |
Sector | Health | Financials |
52-Week High | $12.82 | $27.29 |
52-Week Low | $6.22 | $19.60 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.69B | $16.07B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.
The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.
ONB trades at $24.62, down 0.73% on the day, with a neutral technical outlook and key support at $24. The company shows strong fundamentals, with a P/E of 10.89 and net income margin of 31.39%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights upcoming Q3 earnings and positive institutional investment activity.
The outlook for ONB is positive, supported by robust earnings growth and a 'Buy' consensus from analysts with a $29.67 price target. Key risks include potential earnings volatility and macroeconomic pressures on the banking sector. Upside potential exists if the company continues its trend of exceeding earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Old National Bancorp Common Stock
Old National Bancorp is the bank holding company for Old National Bank, providing consumer banking, commercial banking, wealth management, and capital markets services across Indiana, Kentucky, Michigan, Minnesota, and Wisconsin.
Read more on ONB →
